Stefan Dübel

ORCID iD
https://orcid.org/0000-0001-8811-7390

Biography

Dr. Stefan Dübel is full Professor of Biotechnology and Director of the respective department at the Technische Universität Braunschweig, Germany (http://www.bbt.tu-bs.de/Biotech). He further serves as director of the technology transfer unit "Centre for Molecular Engineering" of iTUBSmbH and as consultant to biotech / pharma companies and US/EU goverment institutions. He initiated the "Antibody factory" of the German National Gemome Research Network and is editor of the four volume "Handbook of Therapeutic Antibodies" and other antibody engineering books. He is co-founder of several biotech companies, most recently of the human antibody discovery and antibody engineering company Yumab GmbH (www.yumab.com). After obtaining his Ph.D. from the Universitiy of Heidelberg, in 1989 he joined the German Cancer Research Center (DKFZ) where he co-pioneered in vitro antibody selection technologies, resulting in several key inventions including antibody phage display (e.g. US Patent 5849500), human antibody libraries (e.g. US6319690) and antibody libraries with randomised CDRs (e.g. US Patent 5840479). His lab continued to contribute to multiple topics related to human antibody engineering, phage display and in vitro evolution, e.g. Hyperphage technology (2001), ORFeome display (2006), and targeted RNases for cancer therapy (1995/2008). Other achievements include the developed the world's first protein knock down mouse using intrabodies (2014), and a universal allosteric switch module for antibody affinity (2017). His work resulted in >200 publications and >25 patent applications.

Record last modified Nov 3, 2018 12:37:09 PM